# Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

> **NCT02534350** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 61 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **DRUG:** Presatovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02534350
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2017-02-20
- **Final completion:** 2017-09-27
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02534350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02534350, "Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02534350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*